CG Oncology

Cg Oncology

Biotechnology, 400 Spectrum CTR Dr Ste 2040, Irvine, California, 92618, United States, 11-50 Employees

cgoncology.com

  • twitter
  • LinkedIn

Who is CG ONCOLOGY

CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where uro...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from CG ONCOLOGY

CG Oncology Org Chart and Mapping

Jennifer Franco

Senior Executive Assistant to Chief Executive Officer & Chief Medical Officer

VP-Level
Employees

Trung Thai

Director, Information Technology

Calvin Lai

Director, Business Development

Ruben Sanchez

Vice President Regulatory Affairs

Kara Sabourin

Director, Clinical Operations

Todd Grempel

Global Head of Human Resources

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding CG Oncology

Answer: CG Oncology's headquarters are located at 400 Spectrum CTR Dr Ste 2040, Irvine, California, 92618, United States

Answer: CG Oncology's official website is https://cgoncology.com

Answer: CG Oncology's revenue is $1 Million to $5 Million

Answer: CG Oncology's SIC: 2834

Answer: CG Oncology has 11-50 employees

Answer: CG Oncology is in Biotechnology

Answer: CG Oncology contact info: Phone number: Website: https://cgoncology.com

Answer: CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO (nivolumab).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access